Skip to main content

Table 1 Combination index (CI) and dose reduction index (DRI) values for valproic acid (VPA), simvastatin (SIM) and docetaxel (DTX) combinations accordingly to different treatment schedules

From: Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition

Cell Lines

VPA + DTX

SIM + DTX

VPA + SIM + DTX

VPA + SIM→DTX

DTX→ VPA + SIM

PC3

aCI50: 0.930.05

bDRI50VPA:1.4 ± 0.07

DRI50 DTX: 4.7 ± 0.94

CI50: 0.95 ± 0.06

DRI50SIM:1.42 ± 0.13

DRI50 DTX:4.8 ± 2.8

CI50: 0.71 ± 0.06

DRI50 VPA:3.1 ± 0.05

DRI50 SIM:3.8 ± 1.7

DRI50 DTX: 10.9 ± 2.55

CI50: 0.62 ± 0.17

DRI50 VPA:4.06 ± 1.89

DRI50 SIM:3.49 ± 1.0

DRI50 DTX: 18.4 ± 4.4

CI50: 0.54 ± 0.06

DRI50 VPA: 5.3 ± 0.6

DRI50 SIM: 3.9 ± 0.5

DRI50 DTX: 10.2 ± 2.76

22Rv1

CI50: 0.7 ± 0.09

DRI50 VPA: 2.3 ± 0.55

DRI50 DTX: 3.07 ± 0.9

CI50: 0.55 ± 0.13

DRI50 SIM:2.9 ± 0.4

DRI50DTX:4.2 ± 1.75

CI50: 0.48 ± 0.1

DRI50 VPA:6.0 ± 1.5

DRI50 SIM:5.4 ± 1.9

DRI50 DTX: 7.3 ± 0.22

CI50: 0.55 ± 0.13

DRI50 VPA:2.3 ± 0.5

DRI50 SIM:4.05 ± 1.82

DRI50 DTX: 4.05 ± 1.82

CI50: 0.48 ± 0.1

DRI50 VPA: 6.0 ± 1.5

DRI50 SIM: 5.4 ± 1.9

DRI50 DTX: 9.8 ± 4.3

DU145

CI50: 0.87 ± 0.14

DRI50 VPA:1.9 ± 0.2

DRI50 DTX: 3.9 ± 0.5

CI50: 0.86 ± 0.2

DRI50SIM:2.42 ± 01.2

DRI50DTX:2.54 ± 0.2

CI50: 0.65 ± 0.03

DRI50 VPA:2.84 ± 0.1

DRI50 SIM:6.46 ± 2.3

DRI50 DTX: 6.99 ± 0.6

CI50: 0.64 ± 0.04

DRI50 VPA:0.45 ± 0.07

DRI50 SIM:5.65 ± 2.05

DRI50 DTX:18.3 ± 0.03

CI50: 0.84 ± 0.02

DRI50 VPA: 2.32 ± 0.03

DRI50 SIM: 5.35 ± 0.07

DRI50 DTX: 4.33 ± 0.38

DUR80

CI50: 0.67 ± 0.15

DRI50 VPA:1.9 ± 0.6

DRI50 DTX: 6.59 ± 0.8

CI50: 0.54 ± 0.2

DRI50SIM:53.9 ± 14.5

DRI50DTX:2.02 ± 0.7

CI50: 0.67 ± 0.02

DRI50 VPA:2.02 ± 0.2

DRI50 SIM:194.5 ± 20

DRI50 DTX: 7.3 ± 1.9

CI50: 0.51 ± 0.25

DRI50 VPA:2.5 ± 1.4

DRI50 SIM:216.1 ± 0.07

DRI50 DTX:19.9 ± 0.05

CI50: 0.65 ± 0.02

DRI50 VPA: 2.21 ± 0.01

DRI50 SIM: 179.6 ± 0.14

DRI50 DTX: 4.49 ± 0.62

  1. Cell growth assessment was done by sulforhodamine B colorimetric assay (see Methods). aCIs values (mean ± S.D.) from at least three separate experiments performed in quadruplicate) computed at 50% of cell kill (CI50) by CalcuSyn software (Biosoft,Cam- bridge, UK). CIs smaller than 0.8 indicate strong synergism; CIs smaller than 0.9 indicate sinergysm; additivity between 0.9 and 1.2 or antagonism more than. Equipotent doses (50:50 cytotoxic ratio) of each of the two agents were evaluated after 96 h with a simultaneous (VPA + DTX: SIM + DTX or VPA + SIM + DTX) or sequential exposure with 24 h delay to either drug (VPA + SIM → DTX; DTX → VPA + SIM) as described in Methods section
  2. bDRI values (mean ± S.D.) from at least three separate experiments performed in quadruplicate) represent the order of magnitude (fold) of dose reduction obtained for IC50 (DRI50) in combination setting compared with each drug alone